{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:01Z","timestamp":1767134881289,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd007003","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000}}],"reference-count":75,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007003.pub2","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T09:49:15Z","timestamp":1439977755000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interventions for dialysis patients with hepatitis C virus (HCV) infection"],"prefix":"10.1002","volume":"2015","author":[{"given":"Ravindra A","family":"Prabhu","sequence":"first","affiliation":[{"name":"Kasturba Medical College and Hospital Manipal, Manipal University; Department of Nephrology; PO Box 7 Madhav Nagar Manipal Karnataka India 576104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekumar","family":"Nair","sequence":"additional","affiliation":[{"name":"Manipal University; Department of Statistics; 6th Floor, Health Sciences Library Building Madhav Nagar Manipal Karnataka India 576 104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Pai","sequence":"additional","affiliation":[{"name":"Kasturba Medical College, Manipal University; Department of Gastroenterology; Madhav Nagar Manipal Karnataka India 576104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageswara P","family":"Reddy","sequence":"additional","affiliation":[{"name":"Kasturba Medical College, Manipal University; Department of Nephrology; Madhavnagar Street Manipal Karnataka India 576104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Suvarna","sequence":"additional","affiliation":[{"name":"Kasturba Medical College, Manipal University; Department of Gastroenterology; Madhav Nagar Manipal Karnataka India 576104"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0001|cit1","first-page":"110","article-title":"Long-term follow up of haemodialysis (HD) patients with chronic hepatitis C (HCV) infection - favorable outcome with \u03b1-interferon (IFN) followed by kidney transplantation [abstract no: M221]","volume":"17","author":"Alfurayh","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD007003.pub2-BIB0002|cit2","first-page":"A106","article-title":"Randomised controlled trial of interferon-\u03b1 (ifn \u03b1) in patients with chronic hepatitis C (HCV) on haemodialysis (HD) [abstract]","volume":"15","author":"Alfurayh","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Sept","key":"10.1002\/14651858.CD007003.pub2-BIB0003|cit3","first-page":"255A","article-title":"IFNalpha for chronic hepatitis C infection (HCV) in haemodialysis (HD) patients - a prospective, randomised, controlled study [abstract]","volume":"11","author":"Alfurayh","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0004|cit4","first-page":"80","article-title":"Efficacy and tolerability of a-2b interferon in the treatment of virus C chronic hepatitis in an hemodialysis population [abstract no: 309]","volume":"16","author":"Campistol","year":"1996","journal-title":"Nefrolog\u00eda"},{"issue":"11","key":"10.1002\/14651858.CD007003.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/ndt\/14.11.2704","article-title":"Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment","volume":"14","author":"Campistol","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 (Pt 2)","key":"10.1002\/14651858.CD007003.pub2-BIB0006|cit6","first-page":"116A","article-title":"A double-blind controlled trial of recombinant interferon alfa in hemodialysis patients with chronic hepatitis C [abstract]","volume":"22","author":"Fernandez","year":"1995","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD007003.pub2-BIB0007|cit7","first-page":"1446","article-title":"A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C [abstract no: A0989]","volume":"7","author":"Fernandez","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2893.1997.tb00213.x","article-title":"A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection","volume":"4","author":"Fernandez","year":"1997","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"10.1002\/14651858.CD007003.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000046646","article-title":"Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C","volume":"21","author":"Huraib","year":"2001","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub2-BIB0010|cit10","first-page":"525","article-title":"Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study","volume":"57","author":"Liu","year":"2008","journal-title":"Hepatitis"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0011|cit11","first-page":"703A","article-title":"Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis patients [abstract]","volume":"42","author":"Luxon","year":"2005","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007003.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/S0168-8278(08)61001-6","article-title":"Low-dose peginterferon alfa-2A (40KD) (PEGASYS\u00ae) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: final study results [abstract no: 999]","volume":"48","author":"Peck-Radosavljevic","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2010.10.018","article-title":"Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease","volume":"9","author":"Peck-Radosavljevic","year":"2011","journal-title":"Clinical Gastroenterology & Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/S0168-8278(07)62226-0","article-title":"Use of low-dose peginterferon alfa-2a (40 kD) (Pegasys) to treat hepatitis C infected end-stage renal disease patients undergoing haemodialysis: interim results from a randomised study [abstract no: 628]","volume":"46","author":"Peck-Radosavljevic","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfi231","article-title":"Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C","volume":"21","author":"Russo","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0016|cit16","first-page":"399A","article-title":"A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis [abstract]","volume":"40","author":"Russo","year":"2004","journal-title":"Hepatology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007003.pub2-BIB0017|cit17","first-page":"416A","article-title":"Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abstract]","volume":"12","author":"Tuglular","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007003.pub2-BIB0018|cit18","first-page":"318A","article-title":"Treatment of acute HCV in hemodialysis [abstract]","volume":"12","author":"Al-Harbi","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0168-8278(05)80248-X","article-title":"Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha","volume":"18","author":"Ellis","year":"1993","journal-title":"Journal of Hepatology"},{"issue":"94","key":"10.1002\/14651858.CD007003.pub2-BIB0020|cit20","first-page":"362","article-title":"Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?","volume":"16","author":"Mesjasz","year":"2004","journal-title":"Polski Merkuriusz Lekarski"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0021|cit21","unstructured":"Mesjasz J Wiecek A Kokot F Does erythropoietin (rHuEPO) treatment influence the incidence of HCV infection in haemodialyzed patients? [abstract] 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sep 17-20; Nice, France 2000 233"},{"issue":"6","key":"10.1002\/14651858.CD007003.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1831-4","DOI":"10.1016\/j.transproceed.2004.07.025","article-title":"Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C","volume":"36","author":"Mousa","year":"2004","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.meg.0000252626.73172.f3","article-title":"Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance","volume":"19","author":"Rocha","year":"2007","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"8410","key":"10.1002\/14651858.CD007003.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(84)91153-X","article-title":"Prevention of non-A, non-B hepatitis in haemodialysis patients by hepatitis B immunoglobulin","volume":"2","author":"Simon","year":"1984","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007003.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0026|cit26","first-page":"993A","article-title":"Peginterferon alfa-2a plus low dose ribavirin versus peginterferon alfa-2a monotherapy for dialysis patients with hepatitis C virus genotype 1 infection: a randomized trial [abstract]","volume":"56","author":"Liu","year":"2012","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0027|cit27","first-page":"1096A","article-title":"Peginterferon alfa-2a with or without low dose ribavirin for hemodialysis patients with hepatitis C virus genotype 2 infection: a randomized trial [abstract]","volume":"58","author":"Liu","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.14309\/00000434-201310001-00513","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial [abstract]","volume":"108","author":"Basu","year":"2013","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.1016\/S0016-5085(13)63533-7","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial [abstract no:517]","volume":"144","author":"Basu","year":"2013","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD007003.pub2-BIB0031|cit31","first-page":"S362","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial [abstract no: P196]","volume":"28","author":"Basu","year":"2014","journal-title":"Surgical Endoscopy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0032|cit32","first-page":"S244","article-title":"Telaprevir with adjusted dose of ribavirin in Naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. TARGET C Trial-a placebo randomized control clinical trial [abstract]","volume":"20","author":"Basu","year":"2014","journal-title":"Liver Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60069-0","article-title":"Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET C (RCT) [abstract no: 67]","volume":"58","author":"Basu","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD007003.pub2-BIB0034|cit34","first-page":"181","article-title":"Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection","volume":"4","author":"Alavian","year":"2010","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.14.255","article-title":"Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C","volume":"14","author":"Ayaz","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0036|cit36","first-page":"1447","article-title":"Antiviral chemotherapy excluding antiretroviral drugs","volume-title":"Harrison's principles of internal medicine","volume":"1","author":"Baden","year":"2012"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2004.12.014","article-title":"Hepatitis C infection is acquired pre-ESRD","volume":"45","author":"Bergman","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"287-92","DOI":"10.1046\/j.1365-2893.2001.00300.x","article-title":"Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study","volume":"8","author":"Bruchfeld","year":"2001","journal-title":"Journal of Viral Hepatitis"},{"issue":"10","key":"10.1002\/14651858.CD007003.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2893.2007.00853.x","article-title":"Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis","volume":"14","author":"Butt","year":"2007","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"10.1002\/14651858.CD007003.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000080883","article-title":"Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure","volume":"47","author":"Chandra","year":"2004","journal-title":"Intervirology"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Chaparro M Trapero-Marugan M Moreno-Otero R Gisbert JP Azathioprine plus ribavirin treatment and pancytopenia Alimentary Pharmacology & Therapeutics 2009 962 3 19807727","DOI":"10.1111\/j.1365-2036.2009.04109.x"},{"issue":"4902","key":"10.1002\/14651858.CD007003.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"6","key":"10.1002\/14651858.CD007003.pub2-BIB0043|cit43","first-page":"585","article-title":"Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis","volume":"23","author":"Dattolo","year":"2006","journal-title":"Giornale Italiano di Nefrologia"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","article-title":"American Gastroenterological Association technical review on the management of hepatitis C","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0045|cit45","first-page":"2542-8; 2578-84","article-title":"Chapter 203: Acute viral hepatitis; Chapter 306: Chronic hepatitis","volume-title":"Harrison's principles of internal medicine","volume":"2","author":"Dienstag","year":"2012"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","article-title":"Hepatitis C infection and the patient with end-stage renal disease","volume":"36","author":"Fabrizi","year":"2002","journal-title":"Hepatology"},{"issue":"11-12","key":"10.1002\/14651858.CD007003.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2003.01780.x","article-title":"Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients","volume":"18","author":"Fabrizi","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"11-12","key":"10.1002\/14651858.CD007003.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","article-title":"Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD007003.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD007003.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2893.2008.00990.x","article-title":"Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials","volume":"15","author":"Fabrizi","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2893.2007.00907.x","article-title":"Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials","volume":"15","author":"Fabrizi","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2893.1999.t01-1-6120131.x","article-title":"Hepatitis C viral quasispecies","volume":"6","author":"Gomez","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0053|cit53","unstructured":"Hassan AA Khalil R Hepatitis C in dialysis patients in Egypt: relationship to dialysis duration, blood transfusion, and liver disease Saudi Journal of Kidney Diseases & Transplantation 2000 72 3 18209303"},{"issue":"7414","key":"10.1002\/14651858.CD007003.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0056|cit56","first-page":"20","article-title":"Interferon: mechanisms of action and clinical value","volume":"2","author":"Houglum","year":"1983","journal-title":"Clinical Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0272-6386(97)90345-0","article-title":"The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients","volume":"29","author":"Knoll","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/00007890-199504150-00030","article-title":"Interferon-alpha-induced acute renal allograft rejection","volume":"59","author":"Magnone","year":"1995","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\/HCV-coinfected patients receiving ribavirin","volume":"9","author":"Moreno","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"10","key":"10.1002\/14651858.CD007003.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","article-title":"Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy","volume":"11","author":"Nakayama","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5386","key":"10.1002\/14651858.CD007003.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007003.pub2-BIB0062|cit62","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"15","key":"10.1002\/14651858.CD007003.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3748\/wjg.v10.i15.2209","article-title":"Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up","volume":"10","author":"Okuda","year":"2004","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000117573","article-title":"Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures","volume":"28","author":"Rahnavardi","year":"2008","journal-title":"American Journal of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","article-title":"Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety","volume":"98","author":"Russo","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007003.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0272-6386(98)70027-7","article-title":"Risk of death among chronic dialysis patients infected with hepatitis C virus","volume":"32","author":"Stehman-Breen","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.23985","article-title":"Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD007003.pub2-BIB0068|cit68","unstructured":"Thomson Micromedex Drug Information for the Health Care Professional. In: Thomson Micomedix Greenwood Village, Colorado 2006 2585"},{"issue":"7","key":"10.1002\/14651858.CD007003.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/S0041-1345(98)01024-0","article-title":"Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C","volume":"30","author":"Tokumoto","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD007003.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","article-title":"Clinical toxicity of the interferons","volume":"10","author":"Vial","year":"1994","journal-title":"Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0071|cit71","first-page":"35","article-title":"Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium","volume":"6","author":"WHO","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"issue":"8565","key":"10.1002\/14651858.CD007003.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(87)91422-X","article-title":"Inhibition of theophylline metabolism by interferon","volume":"2","author":"Williams","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007003.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2165\/00003088-199019050-00003","article-title":"Clinical pharmacokinetics of interferons","volume":"19","author":"Wills","year":"1990","journal-title":"Clinical Pharmacokinetics"},{"issue":"22","key":"10.1002\/14651858.CD007003.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.3748\/wjg.14.3549","article-title":"Clinical features of adverse reactions associated with telbivudine","volume":"14","author":"Zhang","year":"2008","journal-title":"World journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD007003.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007003","article-title":"Interventions for dialysis patients with hepatitis C virus (HCV) infection","author":"Prabhu","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007003.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007003.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T12:37:19Z","timestamp":1718023039000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007003.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":75,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007003.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]}}}